Categories
coronavirus International

Moderna coronavirus vaccine trial shows promising early results

Volunteers who received Moderna’s Covid-19 vaccine had positive early results, according to the biotech company, which partnered with the National Institutes of Health to develop the vaccine.

The company said a test in 8 healthy volunteers found its experimental vaccine was safe and provoked a strong immune response. It is on an accelerated timetable to begin larger human trials soon.

If future studies go well, the company’s vaccine could be available to the public as early as January, Dr. Tal Zaks, Moderna’s chief medical officer, told CNN.

“This is absolutely good news and news that we think many have been waiting for quite some time,” Zaks said.

These early data come from the Phase 1 clinical trial, which typically studies a small number of people and focuses on whether a vaccine is safe and elicits an immune response.

The results of the study, which was led by the National Institutes of Health, have not been peer reviewed or published in a medical journal.

Moderna, based in Cambridge, Massachusetts, is one of eight developers worldwide doing human clinical trials with a vaccine against the novel coronavirus, according to the World Health Organization. Two others, Pfizer and Inovio, are also in the United States, one is at the University of Oxford in Britain, and four are in China.

Moderna has vaccinated dozens of study participants and measured antibodies in eight of them. All eight developed neutralizing antibodies to the virus at levels reaching or exceeding the levels seen in people who’ve naturally recovered from Covid-19, according to the company.

Neutralizing antibodies bind to the virus, disabling it from attacking human cells.

“We’ve demonstrated that these antibodies, this immune response, can actually block the virus,” Zaks said. “I think this is a very important first step in our journey towards having a vaccine.”

A vaccine specialist who is not involved in Moderna’s work said the company’s results are “great.”

“It shows that not only did the antibody bind to the virus, but it prevented the virus from infecting the cells,” said Dr. Paul Offit, a member of the NIH panel that’s setting a framework for vaccine studies in the US.


While the vaccine had promising results in the lab, it’s not known if it will protect people in the real world. The US Food and Drug Administration has cleared the company to begin Phase 2 trials, which typically involve several hundred of people, and Moderna plans to start large-scale clinical trials, known as Phase 3 trials, in July. These typically involve tens of thousands of people. (Source: cnn.com)

Read More

RELATED POSTS